CG
REGN icon

Colony Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Colony Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.08M Buy
3,747
+1,088
+41% +$855K 0.05% 280
2023
Q2 		$1.91M Sell
2,659
-1,354
-34% -$1.04M 0.03% 351
2023
Q1 		$3.3M Sell
4,013
-88
-2% -$66.4K 0.05% 277
2022
Q4 		$2.96M Buy
4,101
+1,845
+82% +$1.36M 0.04% 310
2022
Q3 		$1.55M Sell
2,256
-244
-10% -$154K 0.03% 364
2022
Q2 		$1.48M Sell
2,500
-1,886
-43% -$1.23M 0.03% 370
2022
Q1 		$3.06M Buy
4,386
+1,380
+46% +$873K 0.05% 305
2021
Q4 		$1.9M Sell
3,006
-4,170
-58% -$2.56M 0.03% 331
2021
Q3 		$4.34M Buy
7,176
+2,188
+44% +$1.36M 0.08% 195
2021
Q2 		$2.79M Buy
4,988
+18
+0.4% +$9.12K 0.06% 262
2021
Q1 		$2.35M Buy
4,970
+771
+18% +$375K 0.05% 283
2020
Q4 		$2.03M Buy
4,199
+558
+15% +$301K 0.05% 273
2020
Q3 		$2.04M Buy
3,641
+1,822
+100% +$1.1M 0.05% 267
2020
Q2 		$1.13M Buy
1,819
+12
+0.7% +$6.81K 0.03% 328
2020
Q1 		$882K Sell
1,807
-137
-7% -$56.5K 0.03% 355
2019
Q4 		$730K Sell
1,944
-8,056
-81% -$2.71M 0.02% 460
2019
Q3 		$2K Buy
+10,000
New +$2.96M ﹤0.01% 694
2017
Q2 		– Sell
-570
Closed -$221K – 440
2017
Q1 		$221K Sell
570
-65
-10% -$24.1K 0.02% 257
2016
Q4 		$233K Buy
+635
New +$241K 0.03% 258
2016
Q1 		– Sell
-1,758
Closed -$954K – 541
2015
Q4 		$954K Buy
1,758
+46
+3% +$24.9K 0.09% 198
2015
Q3 		$796K Sell
1,712
-9
-0.5% -$4.83K 0.09% 193
2015
Q2 		$878K Buy
1,721
+103
+6% +$50.3K 0.09% 198
2015
Q1 		$731K Buy
1,618
+648
+67% +$275K 0.08% 186
2014
Q4 		$398K Buy
970
+520
+116% +$204K 0.04% 268
2014
Q3 		$162K Hold
450
– – 0.02% 329
2014
Q2 		$127K Buy
450
+444
+7,400% +$132K 0.02% 253
2014
Q1 		$2K Buy
+6
New +$1.85K ﹤0.01% 762

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Colony Group's REGN Position: Q3 2023 in Review

Colony Group increased its Regeneron Pharmaceuticals (REGN) stake by 41% in Q3 2023, buying an estimated $855K and bringing the position to 3,747 shares worth $3.08M. The position accounts for 0.05% of the portfolio, ranked #280.

Colony Group first reported a position in REGN in Q1 2014 and has held it in 27 quarters since. The position peaked at $4.34M in Q3 2021. 1,178 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Colony Group held 3,747 shares of Regeneron Pharmaceuticals worth $3.08M as of Q3 2023.
  • Colony Group bought 1,088 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $855K.
  • Regeneron Pharmaceuticals made up 0.05% of Colony Group's portfolio in Q3 2023, its #280 holding.
  • Colony Group first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 27 quarters since.
  • Colony Group's Regeneron Pharmaceuticals position peaked at $4.34M in Q3 2021.
  • 1,178 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.